Department of Medical Laboratory Sciences, Varastegan Institute for Medical Sciences, Mashhad, Iran.
Department of Clinical Biochemistry, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
J Cell Biochem. 2023 Apr;124(4):477-494. doi: 10.1002/jcb.30402. Epub 2023 Mar 26.
The second leading cause of cancer death in women worldwide is breast cancer (BC), and despite significant advances in BC therapies, a significant proportion of patients develop metastasis and disease recurrence. Currently used treatments, like radiotherapy, chemotherapy, and hormone replacement therapy, result in poor responses and high recurrence rates. Alternative therapies are therefore needed for this type of cancer. Cancer patients may benefit from immunotherapy, a novel treatment strategy in cancer treatment. Even though immunotherapy has been successful in many cases, some patients do not respond to the treatment or those who do respond relapse or progress. The purpose of this review is to discuss several different immunotherapy approaches approved for the treatment of BC, as well as different strategies for immunotherapy for the treatment of BC.
全球女性癌症死亡的第二大主要原因是乳腺癌（BC），尽管 BC 治疗取得了重大进展，但仍有相当一部分患者发生转移和疾病复发。目前使用的治疗方法，如放疗、化疗和激素替代疗法，疗效不佳，复发率高。因此，这种类型的癌症需要替代疗法。癌症患者可能受益于免疫疗法，这是癌症治疗中的一种新的治疗策略。尽管免疫疗法在许多情况下已取得成功，但有些患者对治疗无反应，或者那些有反应的患者会复发或进展。本综述的目的是讨论几种已批准用于治疗 BC 的免疫疗法以及用于治疗 BC 的免疫疗法的不同策略。
